Opendata, web and dolomites

NORVAS SIGNED

Therapeutic and Biomarker Potential of long non-coding RNAs in Vascular Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NORVAS project word cloud

Explore the words cloud of the NORVAS project. It provides you a very rough idea of what is the project "NORVAS" about.

inhibition    contribution    eluting    tissue    mortality    nudt6    carotid    rnas    uncovered    atherosclerotic    therapeutic    rupture    describes    natural    continues    antisense    multiple    balloons    inhibitors    aneurysms    influences    mechanisms    risk    mini    human    fgf2    transcriptomic    regulators    acutely    maintaining    biomarker    diagnostic    aneurysm    predicting    pigs    regulatory    experimental    aging    post    translational    profiling    feasibility    morbidity    nats    expression    disease    pathophysiological    samples    utilize    transcriptional    patients    ones    techniques    plaque    material    diseased    received    forms    smooth    muscle    burden    molecular    functionally    cell    recognizing    groups    etiology    local    vivo    ctps1    stroke    models    milieu    stents    collective    gene    micrornas    ruptured    survival    slfnl    rodents    extraordinary    steadily    drug    progression    transcripts    aortic    efforts    subsequent    ldlr    fibroblast    as1    society    rna    cardiovascular    strategies    vascular    limit    coding    vulnerability    modulators    launched    abdominal    plasma    stenosis    homeostasis   

Project "NORVAS" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.vascular-tum.de
 Total cost 1˙493˙125 €
 EC max contribution 1˙493˙125 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 1˙493˙125.00
2    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 0.00

Map

 Project objective

The contribution of cardiovascular disease to human morbidity and mortality continues to steadily increase in our aging European society. In response, extraordinary efforts have been launched to determine the molecular and pathophysiological characteristics of its etiology. The collective work of multiple research groups has uncovered a complex transcriptional and post-transcriptional regulatory milieu, which is believed to be essential for maintaining cardiovascular homeostasis. Recently, non-coding RNAs, especially the ones with antisense capabilities such as microRNAs or ‘natural antisense transcripts’ (NATs) have received much attention. They have been identified as important transcriptional and post-transcriptional inhibitors of gene expression. This current proposal describes the development of novel diagnostic and therapeutic strategies to limit the burden of cardiovascular disease in general, and abdominal aortic aneurysms as well as carotid stenosis and subsequent stroke in particular. Using transcriptomic profiling techniques on human diseased tissue samples, we have identified two NATs (SLFNL-AS1 and NUDT6) as novel crucial regulators of smooth muscle cell survival via targeting CTPS1 and the fibroblast growth factor 2 (FGF2) in the vascular system. We are using disease-relevant experimental in vivo models (rodents and LDLR-/- mini-pigs) to functionally assess how inhibition of these two NATs influences aneurysm progression and atherosclerotic plaque vulnerability. One focus of our studies is to utilize local delivery mechanisms for non-coding RNA modulators, such as drug eluting balloons and stents, to enhance the translational feasibility of our findings. Furthermore, we have access to unique human plasma material from patients with early and advanced forms of aneurysm disease, enabling us to investigate the biomarker value of non-coding RNAs in recognizing patients with acutely ruptured aneurysms, as well as predicting the future risk of rupture.

 Publications

year authors and title journal last update
List of publications.
2018 Antonio Di Gennaro, Ana Carolina Araújo, Albert Busch, Hong Jin, Dick Wågsäter, Emina Vorkapic, Kenneth Caidahl, Per Eriksson, Bengt Samuelsson, Lars Maegdefessel, Jesper Z. Haeggström
Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm
published pages: 1907-1912, ISSN: 0027-8424, DOI: 10.1073/pnas.1717906115
Proceedings of the National Academy of Sciences 115/8 2019-05-10
2017 Nicholas J Leeper, Lars Maegdefessel
Non-coding RNAs: key regulators of smooth muscle cell fate in vascular disease
published pages: 611-621, ISSN: 0008-6363, DOI: 10.1093/cvr/cvx249
Cardiovascular Research 114/4 2019-05-10
2019 Sandeep Kumar, Reinier A. Boon, Lars Maegdefessel, Stefanie Dimmeler, Hanjoong Jo
Role of Noncoding RNAs in the Pathogenesis of Abdominal Aortic Aneurysm
published pages: 619-630, ISSN: 0009-7330, DOI: 10.1161/circresaha.118.312438
Circulation Research 124/4 2019-05-10
2017 Yuhuang Li, Lars Maegdefessel
Non-coding RNA Contribution to Thoracic and Abdominal Aortic Aneurysm Disease Development and Progression
published pages: , ISSN: 1664-042X, DOI: 10.3389/fphys.2017.00429
Frontiers in Physiology 8 2019-05-10
2018 Daniel Y. Li, Albert Busch, Hong Jin, Ekaterina Chernogubova, Jaroslav Pelisek, Joakim Karlsson, Bengt Sennblad, Shengliang Liu, Shen Lao, Patrick Hofmann, Alexandra Bäcklund, Suzanne M. Eken, Joy Roy, Per Eriksson, Brian Dacken, Deepak Ramanujam, Anne Dueck, Stefan Engelhardt, Reinier A. Boon, Hans-Henning Eckstein, Joshua M. Spin, Philip S. Tsao, Lars Maegdefessel
H19 Induces Abdominal Aortic Aneurysm Development and Progression
published pages: 1551-1568, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.117.032184
Circulation 138/15 2019-05-10
2019 Suzanne M. Eken, Tinna Christersdottir, Greg Winski, Traimate Sangsuwan, Hong Jin, Ekaterina Chernogubova, John Pirault, Changyan Sun, Nancy Simon, Hanna Winter, Alexandra Backlund, Siamak Haghdoost, Göran K. Hansson, Martin Halle, Lars Maegdefessel
miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease
published pages: 72-82, ISSN: 2452-302X, DOI: 10.1016/j.jacbts.2018.10.006
JACC: Basic to Translational Science 4/1 2019-05-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORVAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NORVAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More